Skip to main content
Evidence Snapshot

eIF-2-alpha kinase GCN2

CHEMBL5358 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:17:49Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5358
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats eIF-2-alpha kinase GCN2 as ChEMBL target CHEMBL5358, mapped to UniProt Q9P2K8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
eIF-2-alpha kinase GCN2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5358
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9P2K8
eIF-2-alpha kinase GCN2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why eIF-2-alpha kinase GCN2 matters

As of 2026-09-14

eIF-2-alpha kinase GCN2 is reviewed as eIF-2-alpha kinase GCN2 (UniProt Q9P2K8); the current evidence base includes 8 approved drugs, 936 compounds, and 168 assays, with lead potency reaching pChEMBL 8.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 936 compounds, and 168 assays for this target. The dominant activity type is IC50. CHEMBL5200118 is the current potency anchor at pChEMBL 8.7.

Use CHEMBL5200118 as the tractability anchor when discussing potency (pChEMBL 8.7).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 8.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why eIF-2-alpha kinase GCN2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9P2K8, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

936
Total Compounds
168
Total Assays
8
Approved Drugs
IC50: 567.0, KI: 111.0, EC50: 12.0, KD: 121.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5200118
 8.7 IC50 —
No preferred name
CHEMBL5571568
 8.6 IC50 —
No preferred name
CHEMBL5202342
 8.5 IC50 —
No preferred name
CHEMBL475251
 8.5 Kd Clinical
No preferred name
CHEMBL5427321
 8.4 IC50 —

Approved Drugs

Structure Compound First Approval
FEDRATINIB
CHEMBL1287853
 2019
MIDOSTAURIN
CHEMBL608533
 2017
NERATINIB
CHEMBL180022
 2017
BOSUTINIB
CHEMBL288441
 2012
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:17:49Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5358